Ga-NeoB

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Breast CancerMetastatic Neuroendocrine Prostate CancerNewly Diagnosed and Recurrent Glioblastoma

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

1

Ga-NeoB

Novartis

Phase 2

32

Adenocard

Astellas

Preclinical

23

Blenoxane

Bristol-Myers Squibb

Preclinical

14

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

15

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

16

Tianeptine

Pfizer

Preclinical

17

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

18

Bisphosphonate

Amgen

Preclinical

29

4SCAR T Cells

SShenzhen Geno-Immune Medical Institute

Preclinical

110

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

1Show 16 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Breast Cancer3 trials

A Phase I/II, Open-label, Multi-center Trial of [177Lu]Lu-NeoB in Combination With Capecitabine in Adult Patients With Gastrin Releasing Peptide Receptor Positive, Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor-2 Negative Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

Active, not recruiting·Novartis·Preclinical·NCT06247995·20 enrolled

A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative and Gastrin Releasing Peptide Receptor Positive Advanced Breast Cancer Experiencing Early Relapse From (Neo)Adjuvant Endocrine Therapy or Who Have Progressed on Endocrine Therapy in Combination With a CDK4/6 Inhibitor for Advanced Disease

Active, not recruiting·Novartis·Phase 1·NCT05870579·28 enrolled

Assessment of the Diagnostic and Theranostic Potential of Ga Bombesin PET/CT (NeoB) Imaging for Staging of ER/PR + HER2- Breast Cancer Patients With Metastatic Disease: Comparison to Conventional Imaging

Completed·SSt Vincent's Hospital, Sydney·Phase 2·NCT05889728·20 enrolled

Metastatic Neuroendocrine Prostate Cancer1 trial

A Phase I, Open-label, Multi-center Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Active, not recruiting·Novartis·Phase 1·NCT06379217·31 enrolled

Newly Diagnosed and Recurrent Glioblastoma1 trial

Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-NeoB in Combination With Radiotherapy (RT) and Temozolomide (TMZ) in Subjects With Newly Diagnosed Glioblastoma and as a Single Agent in Recurrent Glioblastoma

Active, not recruiting·Novartis·Phase 1·NCT05739942·42 enrolled

Details

Drug Info

Related News